
样式: 排序: IF: - GO 导出 标记为已读
-
The Role of Endoscopy Skills Assessment Tools in Programmatic Assessment Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-29 Elizabeth A. Terry, Ahmed Al Qady, Christen K. Dilly
-
AGA Clinical Practice Update on Sclerosing Mesenteritis: Commentary Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-22 Mark T. Worthington, Jacqueline L. Wolf, Seth D. Crockett, Darrell S. Pardi
The purpose of this American Gastroenterological Association Institute Clinical Practice Update is to review the available evidence for diagnosing and treating, as well as examine opportunities for future research in, sclerosing mesenteritis.
-
-
Influence of Low-dose Acetylsalicylic Acid on Renal Function in Patients With Liver Cirrhosis and Ascites Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-20 Henrik Karbannek, Marina Reljic, Andreas Stallmach, Alexander Zipprich, Cristina Ripoll
-
Transition of Care in Celiac Disease: A Chance to Advance Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-18 Laura Kivelä, Claire Jansson-Knodell, Deborah Goldman, Kalle Kurppa, Alberto Rubio-Tapia
-
Reply Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-17 Saurabh Kedia, Shubi Virmani, Vineet Ahuja
-
Embolization of Patent Paraumbilical Vein for the Treatment of Recurrent Hepatic Encephalopathy and Hepatic Myelopathy Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-17 Zhengyu Wang, Yong Lv, Guohong Han
-
Superior Rectal Arteriovenous Fistula: A Rare Cause of Colon Ischemia Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-17 Shinji Yamashita, Yoshiki Okita, Yuji Toiyama
-
Biomarkers of Histological Response in Lanifibranor-treated Patients With Metabolic Dysfunction-associated Steatohepatitis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-17 Jérôme Boursier, Hugo Hervé, Marine Roux, Manal F. Abdelmalek, Sven M. Francque, Pierre Broqua, Jean-Louis Junien, Jean-Louis Abitbol, Philippe Huot-Marchand, Lucile Dzen, Michael P. Cooreman, Sanjaykumar Patel
Lanifibranor, a pan-peroxisome proliferator-activated receptor agonist, has demonstrated therapeutic efficacy on metabolic dysfunction-associated steatohepatitis (MASH) resolution and fibrosis improvement in the Phase IIb NATIVE study. The histologic endpoints of MASH resolution and fibrosis improvement (E1), MASH resolution without worsening of fibrosis (E2), and fibrosis improvement without worsening
-
VCTE and Liver Transplantation: Is There Still a Role for Liver Biopsy? Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-17 Lucy Meunier, Pauline Bozon-Riviere, Stephanie Faure
-
Early Occurrence of Hepatic Encephalopathy Following Transjugular Intrahepatic Portosystemic Shunt Insertion is Linked to Impaired Survival: A Multicenter Cohort Study Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-15 Martin A. Kabelitz, Lisa Sandmann, Michael Praktiknjo, Jim B. Mauz, Timo Alexander Auer, Tony Bruns, Johannes Chang, Uli Fehrenbach, Jan Hinrichs, Christian Jansen, Roman Kloeckner, Johannes Kluwe, Michael Köhler, Carsten Meyer, Felix Piecha, Maike Rebecca Pollmanns, Cristina Ripoll, Michael Schultheiss, Leon Louis Seifert, Fabian Stöhr, Lukas Sturm, Jonel Trebicka, Alexander Zipprich, Christian Labenz
Hepatic encephalopathy (HE) is a common complication following transjugular intrahepatic portosystemic shunt (TIPS) insertion. However, the prognostic significance of overt HE post-TIPS remains controversial.
-
Testosterone Replacement Reduces Morbidity and Mortality for Most Patients With Cirrhosis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-15 Elliot B. Tapper, Xi Chen, Neehar D. Parikh
Many men with cirrhosis have low testosterone levels. This is associated with sarcopenia, anemia, and poor quality of life. Data are lacking, however, regarding the clinical impact of testosterone replacement.
-
Practical and Impactful Tips for Private Industry Collaborations with Gastroenterology Practices Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-14 John Martin, Vasu Appalaneni, Ekta Gupta, Inessa Khaykis
-
Reply Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-13 Mohan Ramchandani, Zaheer Nabi, Pradev Inavolu
-
Chyloperitoneum due to Small Bowel Volvulus Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-13 Zonglin Li, Yejiang Zhou, Linxia Xu
-
High Rates of Dysplasia in a Population-based Analysis of “Incidental” Barrett’s Esophagus Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-13 Jennifer M. Kolb, Christian Davis, J.Lucas Williams, Jennifer Holub, Nicholas Shaheen, Sachin Wani
Current screening and surveillance in Barrett’s esophagus (BE) identifies only a minority of esophageal adenocarcinomas. Novel testing modalities may allow broadening of indications for BE screening. Whether such efforts are warranted depends on the characteristics of additional BE cases discovered, and their risk of progression. This study used national benchmarking data to characterize “incidental”
-
Needle Track Seeding After Trans-gastric EUS-guided Tissue Sampling: Maybe not as Rare as You Think Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-13 Mehdi Mohamadnejad, Mohammad Al-Haddad
-
Processing Mobility Data Through Artificial Intelligence Can Identify Patterns of Physical Activity in Liver Transplant Candidates Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-13 Rachel Orbuch, Pamela M. Bloomer, Ervic Sejdic, Wuqi Li, Andres Duarte-Rojo
-
Proton Pump Inhibitors for Inducing and Maintaining Remission in Eosinophilic Esophagitis: An Updated Systematic Review and Meta-Analysis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-13 Alfredo J. Lucendo, Lucía Gutiérrez-Ramírez, Antonio Tejera-Muñoz, Javier Molina-Infante, Ángel Arias, EUREOS Guidelines Committee
Proton pump inhibitor (PPI) therapy results in clinical and histological remission in approximately 50% of eosinophilic esophagitis (EoE) patients. We aimed to systematically update this topic due to cumulative data from pediatric/adult populations in wider geographical settings.
-
Perspectives on the International Consensus for Acute Severe Ulcerative Colitis Clinical Trial Design: Enhancing Clarity and Applicability Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-13 Arshdeep Singh, Vandana Midha, Ajit Sood
-
The Impact of Metabolic Dysfunction and Bariatric Surgery on Severity and Outcomes in Alcohol-associated Hepatitis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-12 Rosa Yang, Geetha Ramalingam, Yiwei Hang, Joseph Spengler, Ekaterina Smirnova, Richard K. Sterling
-
Cholecystectomy is a Risk Factor for Microscopic Colitis: A Nationwide Population-based Matched Case Control Study Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-11 David Bergman, Fahim Ebrahim, Jiangwei Sun, John Maret-Ouda, Björn Lindkvist, Anne Peery, Jonas F. Ludvigsson
Studies have linked bile acid malabsorption and microscopic colitis (MC), with some patients with MC responding to treatment with bile acid sequestrants. However, the literature on cholecystectomy as a risk factor for MC is inconclusive. Therefore, we investigated the relationship between cholecystectomy and MC on a nationwide scale to provide more definitive insights.
-
Intestinal Ultrasound Findings and Their Prognostic Value in Early Crohn’s Disease – a Copenhagen IBD Cohort Study Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-11 Gorm Roager Madsen, Mohamed Attauabi, Johan F.K.F. Ilvemark, Klaus Theede, Jacob Tveiten Bjerrum, Flemming Bendtsen, Jakob Benedict Seidelin, Rune Wilkens, Trine Boysen, Johan Burisch
We characterize the sonographic features of Crohn’s disease at diagnosis and evaluate the prognostic value of intestinal ultrasound during the early stage of disease.
-
Refining Risk Estimates of Colorectal Cancer in Steatotic Liver Disease: Insights on Methodological Challenges Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-11 Wei-Chun Cheng, Ching-Nung Wu, Pin-Nan Cheng
-
A Comprehensive Review of Geriatric Syndromes and Assessment in Older Adults With Inflammatory Bowel Diseases Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-11 Margalida Calafat, Bharati Kochar, Ashwin N. Ananthakrishnan
Older patients with inflammatory bowel disease (IBD) constitute an increasingly prevalent population. There is growing recognition of the prevalence and impact of geriatric syndromes on patients with IBD. We aimed to critically review available data on geriatric syndromes in patients with IBD.
-
Diffuse Esophageal Uptake on 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Scan Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-11 Christopher James Shephard, William Jiaen Wang, Bulent Baran
-
Worsening Disease Severity as Measured by I-SEE Associates With Decreased Treatment Response to Topical Steroids in Eosinophilic Esophagitis Patients Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-10 Craig C. Reed, Sean S. LaFata, Timothy S. Gee, Hannah L. Thel, Brenderia A. Cameron, Angela Z. Xue, Akshatha Kiran, Adolfo A. Ocampo, Justin McCallen, Christopher J. Lee, Stephanie A. Borinsky, Walker D. Redd, Trevor S. Barlowe, Rayan N. Kaakati, Cary C. Cotton, Swathi Eluri, Evan S. Dellon
The Index of Severity for Eosinophilic Esophagitis (I-SEE) grades eosinophilic esophagitis (EoE) severity across several domains. We assessed associations between EoE features and severity by I-SEE at diagnosis, and baseline I-SEE and outcomes following topical corticosteroids (tCS).
-
Real-World Effectiveness and Safety of Upadacitinib in Crohn’s Disease: A Multicenter Study Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-08 Jalpa Devi, Anthony Xu, Molly Stone, Anish Patel, Abdul Khan, Nikhil Reddy, Jeremy Klein, Navreet Chowla, Caroline Benson, Bryan Christopher Luu, Katherine Huang, Fnu Jaiprada, Marc Fenster, Ryan Ungaro, Joel Pekow, Amanda M. Johnson, Andres J. Yarur, Richa Shukla, Julia Huecker, Shrinivas Bishu, REBOOT IBD consortium, Martin Gregory, David Dulaney, David T. Rubin, Parakkal Deepak
We aimed to describe the real-world effectiveness and safety of upadacitinib (UPA), an oral Janus kinase 1 inhibitor, in patients with Crohn’s disease (CD).
-
To Treat or Not to Treat – Prospection and Prognosis in IBD Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-07 Fernando Gomollón
-
Resolving Metabolic Dysfunction-associated Steatotic Liver Disease Reduces Subclinical Cardiovascular Damage in Chinese Youths Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-07 Lili Yang, Yanan Qiao, Min Zhao, Bo Xi
-
Economic Benefit of Implementation of Pediatric Transnasal Endoscopy in Eosinophilic Esophagitis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-07 Michael Joseph, Joseph Steinberg, Jacob A. Mark, Thomas Wallach, Nathalie Nguyen
-
A Real-World Study of Cumulative Steroid Burden Among Patients with Eosinophilic Esophagitis in the United States Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-04 Mirna Chehade, David A. Katzka, Sarah Naeger, Ryan B. Thomas, Sarette T. Tilton, Medical Research Group, Juby Jacob-Nara, Amr Radwan
-
Endoscopic En Bloc Vs Piecemeal Resection of Large Colonic Adenomas: Carbon Footprint Post Hoc Analysis of a Randomized Trial Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-03-04 Raphaëlle Grau, Pierre-Jean Cottinet, Minh-Quyen Le, Marion Schaefer, Timothée Wallenhorst, Thomas Rösch, Vincent Lépilliez, Stanislas Chaussade, Jérôme Rivory, Romain Legros, Jean-Baptiste Chevaux, Sarah Leblanc, Pierre Lafeuille, Florian Rostain, Enrique Rodriguez de Santiago, Heiko Pohl, Robin Baddeley, Daniel Grinberg, Charles Buiron, João A. Cunha Neves, Maximilien Barret, Jérémie Albouys, Arthur
Endoscopy makes a significant contribution to the carbon footprint of healthcare. A randomized trial (RESECT-COLON) demonstrated that endoscopic submucosal dissection (ESD) decreases the recurrence rate of large adenomas (>25 mm) vs piecemeal endoscopic mucosal resection (P-EMR), reducing the need for follow-up colonoscopy. We aimed to compare the carbon footprint of those 2 strategies.
-
Liver Decompensation in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: A Real-life Study Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-02-26 Leonardo Stella, Maria Pallozzi, Lucia Cerrito, Francesco Santopaolo, Francesco Tovoli, Clemence Hollande, Sabrina Sidali, Bernardo Stefanini, Claudia Campani, Elisa Pellegrini, Giuseppe Cabibbo, Fabio Marra, Fabio Piscaglia, Antonio Gasbarrini, Maurizio Pompili, Mohamed Bouattour, Francesca Romana Ponziani
Atezolizumab plus bevacizumab (atezobeva) has changed the treatment landscape of advanced hepatocellular carcinoma, but its efficacy and safety in patients with impaired liver function are still debated. This study aimed to evaluate the prognostic impact of baseline liver function and liver decompensation during treatment on clinical outcomes.
-
Risks of 75 major congenital malformations after in utero exposure to thiopurines and anti-TNF for maternal inflammatory bowel disease Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-02-26 Antoine Meyer, Lise Marty, Jérôme Drouin, Alain Weill, Franck Carbonnel, Rosemary Dray-Spira
Limited data are available on the risk of major congenital malformations (MCMs) of thiopurines and anti-tumor necrosis factor (TNF) during pregnancy. In this study, we assess the risk of MCMs associated with maternal exposure to thiopurines and anti-TNF for the treatment of inflammatory bowel disease (IBD) during pregnancy.
-
Gallbladder Cancer and Dysplasia in Cholecystectomy Specimens: A Large Study in High-Incidence Regions of South America Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-02-25 Felix Boekstegers, Carol Barahona Ponce, Erik Morales, Cesar Muñoz-Castro, Cristian Lindner, Ivan Schneider Lira, Belarmino Manques, Alicia Colombo Flores, Catalina Valenzuela, Jaime Castillo, Gonzalo de Toro, Mauricio Almau, Cristina Inklemona, Carolina Ituarte, Gerardo F. Arroyo, Loreto Spencer, Hector Losada, Juan Carlos Araya, Bruno Nervi, Claudio Mengoa Quintanilla, Paola Montenegro, Ana Lineth
Gallstone disease has been causally linked to gallbladder cancer (GBC) via the carcinogenesis model of gallstones and inflammation leading to gallbladder dysplasia then GBC. Efficient GBC prevention through cholecystectomy requires accurate prediction of individual GBC risk, especially in low- and middle-income regions, where studies tend to be small and of low quality, and where financial and surgical
-
Characterization of Screening Strategies for Lynch Syndrome in Latin America Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-02-24 Anthony Vladimir Campos-Segura, Karin Alvarez, Alexis German Murillo Carrasco, Benedito Mauro Rossi, Mabel Bohorquez, Florencia Spirandelli, Claudio Benavides, Aina Balto, Adriana Della Valle, Luisina Inés Bruno, Francisco Lopez-Kostner, Marcia Cruz-Correa, Julio Sanchez Del Monte, Jorge Rugeles, Jesica Magalí Ramirez, Ivana Nascimento, Nora Manoukian Forones, Alicia Maria Cock-Rada, Carlos Reyes-Silva
In Latin America, genetic testing for Lynch syndrome (LS) has been partially implemented. Traditionally, LS diagnosis relied on the Amsterdam criteria and Bethesda guidelines, collectively known as traditional screening (TS). However, TS may miss up to 68% of LS cases. To improve detection rates, universal tumor screening (UTS) has been introduced. UTS involves screening all newly diagnosed patients
-
Cost-Effectiveness of Lynch Syndrome Identification Strategies in Individuals with Colorectal Cancer and the Impact on At-Risk Relatives Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-02-24 Sheila D. Rustgi, Josephine Soddano, Myles Ingram, Heather Hampel, Chin Hur, Fay Kastrinos
Universal screening for Lynch syndrome (LS) is recommended for all patients diagnosed with colorectal cancer (CRC). A benefit of LS screening in CRC is cascade testing (CT), whereby at-risk relatives are tested for the familial pathogenic LS variant and undergo intensive surveillance for CRC prevention/early detection if identified with LS. There is not yet universal uptake of CT; we quantify the impact
-
Long-term Safety and Efficacy of Budesonide Oral Suspension for Eosinophilic Esophagitis: A 4-Year, Phase 3, Open-Label Study Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-02-13 Evan S. Dellon, David A. Katzka, Vincent A. Mukkada, Margaret H. Collins, Gary W. Falk, Camilla A. Richmond, Brian Terreri, Manoj Thakur, Mena Boules, Bridgett Goodwin, Ikuo Hirano
We investigated the long-term safety and efficacy of budesonide oral suspension (BOS) in eosinophilic esophagitis (EoE).
-
Proteomics-guided Biomarker Discovery, Validation, and Pathway Perturbation in Infection-related Acute Decompensation of Cirrhosis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-02-07 Pratibha Garg, Nipun Verma, Arun Valsan, Vivek Sarohi, Trayambak Basak, Tarana Gupta, Parminder Kaur, Samonee Ralmilay, Shreya Singh, Arka De, Madhumita Premkumar, Sunil Taneja, Ajay Duseja, Virendra Singh, Jasmohan S. Bajaj
Inappropriate treatment of infections fuels drug resistance, organ failures, and costs in cirrhosis. We explored proteomics to improve infection diagnosis and management in acutely decompensated (AD) cirrhosis.
-
Extended Risankizumab Treatment in Patients With Crohn’s Disease Who Did Not Achieve Clinical Response to Induction Treatment Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-02-03 Remo Panaccione, Marc Ferrante, Iris Dotan, Julian Panés, Tadakazu Hisamatsu, Peter Bossuyt, Silvio Danese, Alexandra Song, Jasmina Kalabic, Namita Joshi, Javier Zambrano, Yafei Zhang, W. Rachel Duan, Kristina Kligys, Marla C. Dubinsky, James O. Lindsay, Severine Vermeire, Britta Siegmund, Peter M. Irving, Geert D’Haens
The efficacy and safety of extended treatment with risankizumab (RZB), an anti-interleukin-23 p19 monoclonal antibody, were evaluated in patients with moderate to severe Crohn’s disease (CD) who did not achieve clinical response to 12 weeks (W) RZB induction treatment (‘initial nonresponders’).
-
Association of Alcohol and Incremental Cardiometabolic Risk Factors With Liver Disease: A National Cross-sectional Study Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-02-03 Brian P. Lee, Justene Molina, Steve Kim, Jennifer L. Dodge, Norah A. Terrault
New nomenclature allows a single cardiometabolic risk factor (CMRF) with alcohol to classify metabolic dysfunction-associated steatotic liver disease (MASLD) and with “increased alcohol intake” (MetALD), which is controversial because alcohol causes CMRFs. Studies regarding incremental CMRFs and liver-related outcomes among alcohol users would be informative.
-
Colorectal Cancer Incidence in Steatotic Liver Disease (MASLD, MetALD, and ALD) Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-01-31 Takefumi Kimura, Nobuharu Tamaki, Shun-Ichi Wakabayashi, Naoki Tanaka, Takeji Umemura, Namiki Izumi, Rohit Loomba, Masayuki Kurosaki
Obesity and alcohol consumption are established risk factors for colorectal cancer (CRC). Recently, a multisociety consensus group has introduced a new classification for steatotic liver disease (SLD), which encompasses metabolic dysfunction–associated steatotic liver disease (MASLD), MASLD and increased alcohol intake (MetALD), and alcohol-associated liver disease (ALD). However, the risk of developing
-
Diffuse Esophageal Adenocarcinoma Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-01-30 Huijie Wu, Xiaolu Lin, Wanyin Deng
-
Guarding the Gate: The Sentinel Role of Endosonography in Precluding Unwarranted ERCP Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-01-30 Gregory A. Coté, Michael L. Kochman, Nikhil R. Thiruvengadam
-
Interleukin-17A Inhibitor-induced Pouchitis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-01-30 Hiroki Kiyohara, Yohei Mikami, Takanori Kanai
-
Safety and Clinical Effectiveness of GLP1 Receptor Agonists in Inflammatory Bowel Disease Patients Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-01-30 Priya Sehgal, James D. Lewis, Octavia Pickett-Blakely, Neilanjan Nandi, Meena Bewtra, Gary R. Lichtenstein
-
Endoscopic Ultrasound–Guided Portosystemic Pressure Gradient Correlates with Clinical Parameters and Liver Histology Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-01-30 Jennifer M. Kolb, Marc Monachese, Raymond A. Rubin, Thomas J. Wang, Alyssa Choi, Ahmad N. Bazarbashi, Bhaumik Brahmbhatt, Ali Zakaria, Pedro Cortes, Varun Kesar, William F. Abel, Wen-Pin Chen, Christine McLaren, Amirali Tavangar, Amit G. Singal, Pushpak Taunk, Michael B. Wallace, Prashant Kedia, David Lee, Ali Abbas, Paul Yeaton, Natalie Cosgrove, Vivek Kesar, Kenneth J. Chang, Marvin Ryou, Jason Samarasena
Endoscopic ultrasound–guided portosystemic pressure gradient measurement (EUS-PPG) is a novel technique to evaluate for portal hypertension (PH), a diagnosis that can prognosticate and guide therapy for patients. This study evaluated the safety and efficacy of EUS-PPG and correlation with clinical parameters and liver histology.
-
Outcomes in Female Patients With Chronic Liver Disease Undergoing Infertility Treatment Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-01-30 Meera Garriga, Marcelle Cedars, Monika Sarkar
-
Diagnosis of Retrograde Cricopharyngeus Dysfunction Using High Resolution Impedance Manometry and Comparison With Control Subjects Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-01-30 Karlien Raymenants, Friedel Vulsteke, Tim Vanuytsel, Nathalie Rommel, Filip Baert, Kathelijne Delsupehe, Alexandre Bohyn, Jan Tack, Joris Arts
Retrograde cricopharyngeal dysfunction (R-CPD) or inability to belch has been linked to ineffective relaxation of the upper esophageal sphincter (UES) during gastroesophageal gas reflux, and botulinum toxin (BT) injection into the UES has demonstrated success in case series. However, the diagnosis is often overlooked. High resolution impedance manometry (HRiM) with belch provocation was recently suggested
-
Melting the Celiac Iceberg to Improve Outcomes in Celiac Disease: Two Tales of Success Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-01-30 Alberto Rubio-Tapia
-
A Machine Learning Model Score Predicts Advanced Fibrosis and Cirrhosis in Indeterminate FIB-4 Patients Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-01-30 Sebastian Niezen, Timothy R. Morgan, Heather M. Patton, Jasmohan S. Bajaj, Elliot B. Tapper, Shari S. Rogal
-
The Assessment of Gastrointestinal Transit by the Atmo Capsule: A Comparison With the SmartPill Capsule Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-01-30 Braden Kuo, Allen A. Lee, Thomas Abell, Ashok Attaluri, Michael Cline, William Hasler, Vincent Ho, Anthony J. Lembo, Amir Masoud, Richard McCallum, Baharak Moshiree, Eamonn M.M. Quigley, Satish S.C. Rao, Abigail Stocker, Mayra Sanchez, Irene Sarosiek, Brian Surjanhata, Jerry Zhou, William D. Chey
Wireless motility capsules (WMCs) can be used to assess gastrointestinal transit time to facilitate diagnosis and treatment of motility disorders. The Atmo Capsule is a novel WMC that measures gases (H2, CO2, O2) and temperature. We aimed to compare and evaluate the performance characteristics of the Atmo Capsule and the SmartPill Capsule (discontinued reference standard WMC) for measurement of gastric
-
Reply Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-01-30 Julia L. Gauci, Anthony Whitfield, Michael J. Bourke
-
Comprehensive Multidisciplinary Evaluation of Dysphagia Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-01-21 Jessica W. Gregor, David G. Lott, Allon Kahn
-
Gender-Equity Model for Liver Allocation Using Artificial Intelligence (GEMA-AI) for Waiting List Liver Transplant Prioritization Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-01-21 Antonio Manuel Gómez-Orellana, Manuel Luis Rodríguez-Perálvarez, David Guijo-Rubio, Pedro Antonio Gutiérrez, Avik Majumdar, Geoffrey W. McCaughan, Rhiannon Taylor, Emmanuel A. Tsochatzis, César Hervás-Martínez
We aimed to develop and validate an artificial intelligence score (gender-equity model for liver allocation using artificial intelligence [GEMA-AI]) to predict liver transplantation (LT) waiting list outcomes using the same input variables contained in existing models.
-
Lifestyle and Pharmacologic Approaches to Prevention of Metabolic Dysfunction-associated Steatotic Liver Disease-related Hepatocellular Carcinoma Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-01-10 Makan Cheraghpour, Behzad Hatami, Amit G. Singal
Hepatocellular carcinoma (HCC) is a major concern for public health. Fatty liver disease, related to alcohol misuse or metabolic syndrome, has become the leading cause of chronic liver disease and HCC. The strong association between type 2 diabetes mellitus and HCC can be partly attributed to the development of metabolic dysfunction-associated steatotic liver disease (MASLD). There is a strong interest
-
Gastrointestinal and Liver Adverse Effects of Alcohol Use Disorder Medications: A Pharmacovigilance Analysis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-01-10 Soo Young Hwang, Jay Luther, Wei Zhang
-
AGA Clinical Practice Update on Noncolorectal Cancer Screening and Vaccinations in Patients With Inflammatory Bowel Disease: Expert Review Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-01-10 Freddy Caldera, Sunanda Kane, Millie Long, Jana G. Hashash
The aim of this American Gastroenterological Association (AGA) Clinical Practice Update (CPU) is to provide Best Practice Advice statements for gastroenterologists and other healthcare providers who provide care to patients with inflammatory bowel disease (IBD). The focus is on IBD-specific screenings (excluding colorectal cancer screening, which is discussed separately) and vaccinations. We provide
-
Point-of-Care Ultrasound in Gastroenterology and Hepatology Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2025-01-08 Nagasri Shankar, Lily Kuo, Noa Krugliak Cleveland, Benjamin Galen, Nicholas S. Samel, Ariadna Perez-Sanchez, Robert Nathanson, Elizabeth Coss, Juan Echavarria, David T. Rubin, Nilam J. Soni
Point-of-care ultrasound (POCUS) is changing the practice of nearly all specialties and is increasingly being incorporated as a bedside tool by more gastroenterologists and hepatologists. POCUS is most often used to answer focused diagnostic questions, supplement the traditional physical examination, and guide performance of invasive bedside procedures. This review describes several common POCUS applications